Is MaxCyte Inc (MXCT) overvalued? · rev $38.6M
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
This page asks whether MaxCyte Inc (MXCT) looks expensive on cached numbers — not a short thesis.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
MXCT currently screens at market cap $124.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MXCT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MXCT stock page for the full model, not this heading.
Not investment advice.